Finally, we analyzed the relationship between MSI2 expression and prognosis, the overall survival (OS) analysis based on RNA FPKM values from TCGA showed that CRC patients with higher expression of MSI2 had a better prognosis (3 groups, p = 0.051; 4 groups, p = 0.015) (Fig. S10B). Here, MSI2 is linked to colorectal carcinoma.